CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 535 enrolled
Drug / intervention
DOAC or VKA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03134911
NCT03134911N/ACompleted
CompareCT.gov

Non-Interventional, Cross-sectional Study to Describe Health-related Quality of Life Among Controlled and Uncontrolled Patients With Nonvalvular Atrial Fibrillation on Anticoagulants. RE-QUOL Study.

Boehringer Ingelheim·observational·Posted May 1, 2017·Updated Apr 18, 2019

In Brief

An observational study evaluating DOAC or VKA and VKA for Atrial Fibrillation. Completed, enrolled 535 participants across 39 sites.

Detailed Summary

The present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial fibrilation at least 6 months prior to study initiation. It will be conducted in Departments of Internal Medicine from approximately 50 centers in Spain. It consists of an only visit that will coincide with one of those performed by the patients as part of routine follow-up of their disease. 500 patients seen in internal medicine are planned to be included in the study

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 1, 2017
Enrollment StartApr 24, 2017
Primary CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.2 years ago

Interventions

DOAC or VKAdrug

6 months - 2 years

VKAdrug

6 months - 2 years